Autopsy report · NCT02531308

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year before it stopped.
5 participants enrolled.
Results were posted on the registry 6 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Rush University Medical Center
Sponsor type: University, hospital or other
Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Metformin; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone
Participants: 5
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.